Skip to main content
. 2020 Jun 17;113(3):309–317. doi: 10.1093/jnci/djaa087

Figure 3.

Figure 3.

Association between ctDNA genomic features and progression-free survival (PFS). A) Univariable analyses of PFS by detected genomic aberrations for the palbociclib plus fulvestrant group. B) Univariable analyses of PFS by detected genomic aberrations for the placebo plus fulvestrant group. The size of bubble indicates the prevalence within the treatment group. P values are log-rank. P value correction is with the Benjamini-Hochberg method to give Q values. ctDNA = circulating tumor DNA.